|Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.||Co-Founder, CEO & Director||412.64k||N/A||N/A|
|Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D.||Co-Founder, COO and Exec. VP of Project Management, Non Clinical & Manufacturing Operations||N/A||N/A||N/A|
|Dr. Pascale Fouqueray-Grellier M.D., Ph.D.||Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs||N/A||N/A||N/A|
|Dr. Sophie Hallakou-Bozec Ph.D.||Co-Founder and Exec. VP of R&D Pharmacology & Scientific Communication||N/A||N/A||N/A|
|Mr. Quentin Durand||Exec. VP, Chief Legal Officer & Head of Corp. Social Responsibility||N/A||N/A||N/A|
|Ms. Sylvie Bertrand||VP of HR||N/A||N/A||N/A|
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Poxel S.A.’s ISS governance QualityScore as of 28 September 2023 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 4; Compensation: 10.